Birsfelden, Switzerland

Regine Peter


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Regine Peter: Innovator in Pharmaceutical Chemistry

Introduction

Regine Peter is a notable inventor based in Birsfelden, Switzerland. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of polymorphic forms of sertraline hydrochloride. Her work has implications for drug absorption and efficacy.

Latest Patents

Regine Peter holds a patent for "Polymorphic forms of sertraline hydrochloride." This patent describes a crystalline form of sertraline hydrochloride, referred to as polymorphic form CSC2, which exhibits a dissolution rate that surprisingly enhances the absorption rate of the drug. Additionally, her patent discloses various crystalline forms of sertraline hydrochloride, including alcohol solvates and hydrates, as well as a process for preparing the amorphous form of sertraline hydrochloride. The patent also details different processes for the preparation of polymorphic forms I, II, V, and T1.

Career Highlights

Regine Peter is associated with Ciba Specialty Chemicals Corporation, where she has been able to apply her expertise in pharmaceutical development. Her innovative work has contributed to advancements in drug formulation and delivery.

Collaborations

Regine has collaborated with esteemed colleagues such as Paul Adriaan Van Der Schaaf and Franz Schwarzenbach, further enhancing her research and development efforts in the pharmaceutical industry.

Conclusion

Regine Peter's contributions to the field of pharmaceutical chemistry, particularly through her patent on sertraline hydrochloride, highlight her role as an innovator in drug development. Her work continues to influence the effectiveness of pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…